Enhancement of susceptibility to diverse skin tumor promoters by activation of the insulin-like growth factor-1 receptor in the epidermis of transgenic mice

Molecular Carcinogenesis

Volumn 25, Issue 2, 1999, Pages 122-131

  Wilker, Erik ^a   Bol, David ^a   Kiguchi, Kaoru ^a   Rupp, Tim ^a   Beltrán, Linda ^a   DiGiovanni, John ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Insulin like growth factor 1; Insulin like growth factor 1 receptor; Skin tumorigenesis

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; BENZOYL PEROXIDE; CHRYSAROBIN; OKADAIC ACID; SOMATOMEDIN C RECEPTOR; TUMOR PROMOTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; HISTOPATHOLOGY; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN TUMOR; TRANSGENIC MOUSE; TUMOR PROMOTION;

ANIMALS; ANTHRACENES; BENZOYL PEROXIDE; CARCINOGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MICE, TRANSGENIC; OKADAIC ACID; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE; TRANSGENES;

ANIMALIA; MUS MUSCULUS;

EID: 0033059976     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199906)25:2<122::AID-MC7>3.0.CO;2-8     Document Type: Article

References (47)

1. Bol D, Kiguchi K, Gimenez-Conti I, Rupp T, DiGiovanni J. Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice. Oncogene 1997;14:1725-1734.
2. Rothnagel JA, Longley MA, Bundman D, Greenhalgh DA, Dominey AM, Roop DR. Targeting gene expression to the epidermis of transgenic mice: Potential applications to genetic skin disorders. J Invest Dermatol 1990;95:59S-61S.
3. Greenhalgh DA, Rothnagel JA, Quintanilla MI, et al. Induction of epidermal hyperplasia, hyperkeratosis, and papillomas in transgenic mice by a targeted v-Ha-ras oncogene. Mol Carcinog 1993;7:99-110.
4. Yee D, Paik S, Lebovic G, et al. Analysis of insulin-like growth factor I gene expression in malignancy: Evidence for a paracrine role in human breast cancer. Mol Endocrinol 1989;3:509-517.
5. Tricoli J, Rall L, Karakousis et al. Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res 1986;46:6169-6173.
6. Minuto F, Del Monte P, Barreca A, et al. Evidence for an increased somatomedin-C/insulin-like growth factor 1 content in primary human lung tumors. Cancer Res 1986;46:985-988.
7. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998;279:563-566.
8. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-1396.
9. Rho O, Bol D, You J, Beltran L, Rupp T, DiGiovanni J. Altered expression of insulin-like growth factor 1 and its receptor during multistage carcinogenesis in mouse skin. Mol Carcinog 1996;17:62-69.
10. Dunn SE, Kari FW, French J, et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997;57:4667-4672.
11. Kaleko M, Rutter W, Miller A. Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 1990;10:464-473.
12. Dawson TP, Radulescu A, Wynford-Thomas D. Expression of mutant p21ras induces insulin-like growth factor 1 secretion in thyroid epithelial cells. Cancer Res 1995;55:915-920.
13. Vardy D, Kari C, Lazarus G, et al. Induction of autocrine epidermal growth factor receptor ligands in human keratinocytes by insulin/insulin-like growth factor-1. J Cell Physiol 1995; 163:257-265.
14. Sell C, Rubini M, Rubin R, Liu J-P, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonicfibroblasts lacking type-1 IGF receptor. Proc Natl Acad Sci USA 1993;90:11217-11221.
15. Sell C, Dumenil G, Deveaud C, et al. Effect of a null mutation of the type 1 IGF receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 1994;14:3604-3612.
16. DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmacol Ther 1992;48:63-128.
17. DiGiovanni J. Role of TGFa and the EGF receptor in multistage skin carcinogenesis. In: Mukhtar H, editor. Skin cancer: mechanisms and human relevance. Boca Raton, FL: CRC Press, Inc.: 1995. p 181-197.
18. Krane J, Murphy D, Carter D, Krueger J. Synergistic effects of epidermal growth factor (EGF) and insulin-like growth factor 1 somatomedin C (IGF-1) on keratinocyte proliferation may be mediated by IGF-1 transmodulation of the EGF receptor. J Invest Dermatol 1991;96:419-424.
19. Burgaud JL, Baserga R. Intracellular transactivation of the insulin-like growth factor 1 by an epidermal growth factor receptor. Exp Cell Res 1996;223:412-419.
20. DiGiovanni J, Boutwell RK. Tumor promoting activity of 1,8-dihydroxy-3-methyl-9-anthrone (chrysarobin) in female SENCAR mice. Carcinogenesis 1993;4:281-284.
21. 3H]thymidine administered by injection or osmotic pump. Carcinogenesis 1990;4:281-284.
22. Naito M, Naito Y, DiGiovanni J. Comparison of the histological changes in the skin of DBA/2 and C57BL/6 mice following exposure to various promoting agents. Carcinogenesis 1987;8:1807-1815.
23. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
24. DiGiovanni J, Walker SE, Aldaz CM, Slaga TJ, Conti CJ. Further studies on the influence of initiator dose on papilloma growth and progression during two-stage carcinogenesis in SENCAR mice. Carcinogenesis 1993;14:1831-1836.
25. DiGiovanni J, Walker SC, Beltran L, Naito M, Eastin WC. Evidence for a common genetic pathway controlling susceptibility to mouse skin tumor promotion by diverse classes of promoting agents. Cancer Res 1991;51:1398-1405.
26. Imamoto A, Beltran L, DiGiovanni J. Evidence of autocrine/ paracrine growth stimulation by transforming growth factor a during the process of skin tumor promotion. Mol Carcinog 1991;4:52-60.
27. Kiguchi K, Beltran LM, You J, Rho O, DiGiovanni J. Elevation of transforming growth factor-α mRNA and protein expression by diverse tumor promoters in SENCAR mouse epidermis. Mol Carcinog 1995;12:225-235.
28. Kiguchi K, Beltran L, Rupp T, DiGiovanni J. Altered expression of epidermal growth factor receptor ligands in tumor promoter-treated mouse epidermis and in primary mouse skin tumors by an initiation-promotion protocol. Mol Carcinog 1998;22:73-83.
29. Baserga R The insulin-like growth factor 1 receptor: A key to tumor growth? Cancer Res 1995;55:249-252.
30. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B. The IGF-1 receptor in cell growth, transformation and apoptosis. Biochem Biophys Acta 1997;1332:F105-F126.
31. Xian W, Kiguchi K, Imamoto A, RuppT, Zilberstein A, DiGiovanni J. Activation of the epidermal growth factor receptor by skin tumor promoters and in skin tumors from SENCAR mice. Cell Growth Differ 1995;6:1447-1455.
32. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 1995;16:3-34.
33. Aaronson SA. Growth factors and cancer. Science 1991;254: 1146-1153.
34. Dlugosz A, Cheng C, Denning MF, Dempsey P, Coffey R, Yuspa S. Keratinocyte growth factor receptor ligands induce transforming growth factor a expression and activated the epidermal growth factor receptor signaling pathway in cultured epidermal keratinocytes. Cell Growth Differ 1994;5:1283-1292.
35. Neely E, Morhenn V, Hintz R, Wilson D, Rosenfeld R. Insulin-like growth factors are mitogenic for human keratinocytes and squamous cell carcinoma. J Invest Dermatol 1991;96:104-110.
36. Barreca A, De Luca M, Del Monte P, et al. In vitro paracrine regulation of human keratinocyte growth by fibroblast-derived insulin-like growth factors. J Cell Physiol 1992;151:262-268.
37. Le Roith D, Parrizas M, Blakesley V. The insulin-like growth factor-1 receptor and apoptosis. Endocrine 1997;7:103-105.
38. White M, Kahn CR. The insulin signaling system. J Biol Chem 1994;269:1-4.
39. O'Connor R, Kauffmann-Zeh A, Liu Y, et al. Identification of domains of the insulin-like growth factor 1 receptor that are required for protection from apoptosis. Mol Cell Biol 1997; 17:427-435.
40. Parriazas M, Saltiel A, LeRoith D. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. J Biochem 1997;272:154-161.
41. Kulik G, Klippel A, Weber M. Anti-apoptotic signaling by the insulin-like growth factor-1 receptor, phosphatidylinositol 3-kinase and AKT. Mol Cell Biol 1997;17:1595-1606.
42. Pahlman S, Myerson G, Lingren E, Schalling M, Johansson I. Insulin-like growth factor I shifts from promoting cell division to potentiating maturation during neuronal differentiation. Proc Natl Acad Sci USA 1991;88:9994-9998.
43. Rosenthal S, Hsiao D, Silverman L. Insulin-like growth factor-II (IGF-II) analog with highly selective affinity for IGF-II receptors stimulates differentiation, but not OGF-1 receptor down-regulation in muscle cells. Endocrinology 1994;135:38-44.
44. Pena J, Rudin C, Thompson C. A BCL-XL transgene promotes malignant conversion of chemically initiated skin papillomas. Cancer Res 1998;58:2111-2116.
45. Rodriguez-Villanueva J, Greenhalgh D, Wang X-J, et al. Human keratin-1.bcl-2 transgenic mice aberrantly express keratin 6, exhibit reduced sensitivity to keratinocyte cell death induction, and are susceptible to skin tumor formation. Oncogene 1998;16:853-863.
46. Franke T, Cantley L. A bad kinase makes good. Nature 1997; 390:116-117.
47. Carlberg M, Dricu A, Blegen H, et al. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme A reductase and cell growth. J Biol Chem 1996;271: 17453-17462.